Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's Jelly-derived Mesenchymal Stem Cells (Medical University of Warsaw)
- Development stage
- Unknown
- Lead developer
- Medical University of Warsaw
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Wharton's Jelly-derived Mesenchymal Stem Cells (WJMSC) are a population of multipotent progenitor cells harvested from the umbilical cord matrix. These cells are being investigated by the Medical University of Warsaw for the treatment of osteoarthritis in the knee, hip, and glenohumeral joints. WJMSCs possess significant immunomodulatory and anti-inflammatory properties, exerting their therapeutic effects primarily through paracrine signaling. They secrete a variety of cytokines, growth factors, and extracellular vesicles that help to reduce joint inflammation, inhibit the degradation of the extracellular matrix, and potentially stimulate endogenous cartilage repair mechanisms. In clinical trials led by the Medical University of Warsaw, these cells are sourced from the Polish Stem Cell Bank and administered via ultrasound-guided intra-articular injection.
- Other names
- Wharton's Jelly Mesenchymal Stem CellsWJMSC-Medical University of WarsawWJMSC-MUW
Beyond the preview
Go deeper on Wharton's Jelly-derived Mesenchymal Stem Cells (Medical University of Warsaw).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's Jelly-derived Mesenchymal Stem Cells (Medical University of Warsaw).